

Prilenia is a clinical-stage biotechnology company

dedicated to developing new treatments for the urgent needs facing patients and families living with Huntington's disease, ALS, and other neurodegenerative diseases and neurodevelopmental disorders.

PRIDOPIDINE

Pridopidine is a first-in-class, investigational highly selective and potent sigma-1-receptor (S1R) agonist with neuroprotective properties. It is administered by mouth in a small, easy-to-swallow capsule twice daily. Pridopidine has been studied in more than 1,650 people and long-term safety data are available from previous clinical studies, some running up to 5 years. In these investigational studies, pridopidine at the therapeutic dose has an observed safety and tolerability profile comparable to placebo. Pridopidine is currently in late-stage development for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).


Prilenia is continuing the clinical and preclinical evaluation of pridopidine in various neurodegenerative diseases and neurodevelopmental disorders and plans to initiate additional clinical studies in the future.

PRIDOPIDINE PIPELINE

INDICATION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Huntington's disease (HD)				
Amyotrophic lateral sclerosis (AL	.S)			
Vanishing White Matter disease*				
Wolfram syndrome				
Rett syndrome				
Fragile X				
Neurodegenerative eye disease				
Alzheimer's disease				
Parkinson's disease				

*Single patient, investigator-sponsored expanded access

Pridopidine is an investigational drug that has not been approved by the FDA. The safety and efficacy of pridopidine have not yet been established.





@PrileniaTx